Here, we assessed the effect of tinostamustine on the expression of CD38 and ligands for activating NK cell receptors in MM cells and subsequently explored its potential to enhance the anti-myeloma effect of daratumumab in preclinical models. This evidence concerns the gene KLRD1 and Miyoshi myopathy.